How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)-Reference-Cited by-同舟云学术

How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)

Published:2020-04-22 Issue:12 Volume:9 Page:4160-4165
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Breccia Massimo¹^ORCID,Olimpieri Pier Paolo²^ORCID,Olimpieri Odoardo²,Pane Fabrizio³,Iurlo Alessandra⁴^ORCID,Foggi Paolo²,Cirilli Alessia²,Colatrella Antonietta²,Cuomo Marcello²,Gozzo Lucia²,Summa Valentina²,Corradini Paolo⁵,Russo Pierluigi²,

Affiliation:

1. Department of Translational and Precision Medicine Az. Policlinico Umberto I‐Sapienza University Rome Italy

2. Italian Medicines Agency Rome Italy

3. Università degli Studi di Napoli Federico II Naples Italy

4. Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano Italy

5. Università degli Studi di Milano & Divisione Ematologia Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano Italy

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3071